Table 2.

Neutralization of HIV-1 by MAbs and CD4-based molecules in PBMC

CellsID50(μg/ml)a
2F52G12sCD4CD4-IgG215e447-52D19b
CCR5 primary
 SF16211.60.035.990.67498.124.6
 JR-FL1.740.0120.10.13>50ND>50
 Case B2-6-924.7>50>501.83>50ND>50
 ADA6.6<0.0829.10.12>50NDND
CCR5 + CXCR4 primary
 DH123>505.825.60.4>50ND>50
 2076 cl126.70.18>5028.3>50NDNB
 P1714.40.0719.61.55NDNDNB
 Case B5/864.880.03>50>50NB>50NB
 89.612.70.0021.040.21>50ND>50
CXCR4 primary
 HC722.2<0.00427.80.76NDND>50
 207518.96.717.30.91>50NDNB
 204426.3>50>508.45>50>50NB
 2005 cl1>500.01>500.91>50NDNB
 ACH-P8.090.00834.42.3>5018.1ND
CCR5 + CXCR4 TCLA
 SF20.070.0030.140.060.32<0.083.21
 C177.80.00824.90.22NDNDNB
CXCR4 TCLA
 NL4-31.980.0020.180.06>50ND>50
 ACH-H91.540.050.310.01>50NDND
 ACH-P/H91.230.0135.30.2>5030.7ND
  • a Derived from one representative experiment out of two to five performed. When no neutralization at 50 μg/ml was observed, a value >50 μg/ml is reported. ND, not done; NB, no binding (i.e., neutralization activity could not be evaluated because the MAb epitope is absent from the viral glycoprotein).